T1	MajorClaim 0 69	Fracture risk is increased in individuals with type 2 diabetes (T2D).
T3	Claim 1805 1861	The choice of insulin treatment is not influencing BTMs,
T4	Claim 1862 1900	metformin treatment may decrease BTMs,
T5	Claim 1905 1977	improvement of glycaemic control may influence bone resorption activity.
T6	Premise 1751 1804	HbA1c was inversely associated with CTX but not P1NP.
T7	Premise 1667 1750	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
T8	Premise 1549 1666	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
T9	Premise 1468 1548	Allocation of insulin regimens was not associated with different levels of BTMs.
T10	Premise 1317 1467	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
R1	Support Arg1:T7 Arg2:T3	
R2	Support Arg1:T9 Arg2:T3	
R3	Support Arg1:T8 Arg2:T4	
